Bal Pharma Share Price | Bal Pharma Stock Screener
BALPHARMA
Pharmaceuticals
Share Price NSE
₹87.34
▼
-1.05 (-1.19%)
Share Price BSE
₹87.08
▼
-1.13 (-1.28%)
As of July 24, 2026, the Bal Pharma share price (NSE: BALPHARMA) is ₹87.34 on NSE and ₹87.08 on BSE, down 1.19% from the previous close, with shares trading between ₹86.21 and ₹87.94, and a 52-week range of ₹60.42–₹100.05.
Analyse BALPHARMA share price history and track historical price performance.
Use the Bal Pharma stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Bal Pharma Market Cap
₹144.35 Cr.
BALPHARMA P/E Ratio (TTM)
21.93
Bal Pharma P/B Ratio
1.69
EPS (TTM)
₹3.95
Dividend Yield
1.38%
Debt to Equity
1.94
BALPHARMA 52 Week High
₹100.05
Bal Pharma 52 Week Low
₹60.42
Operating Margin
13.00%
Profit Margin
4.76%
BALPHARMA Revenue (TTM)
₹84.00
EBITDA
₹10.00
Net Income
₹4.00
Total Assets
₹376.00
Total Equity
₹82.00
Bal Pharma Share Price Chart
Screen Bal Pharma share price with an interactive chart. Analyse BALPHARMA price trends and volatility across different timeframes.
Bal Pharma Company Profile - Fundamental Screener
Screen Bal Pharma company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for BALPHARMA shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE083D01012
Bal Pharma Balance Sheet Screener
Screen BALPHARMA balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 376 | 336 | 320 | 313 | 261 | 240 | 238 | 261 | 260 | 233 |
| Current Assets | 262 | 235 | 234 | 228 | 185 | 164 | 157 | 183 | 185 | 165 |
| Fixed Assets | 98 | 87 | 80 | 77 | 67 | 69 | 71 | 70 | 72 | 60 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 44 | 39 | 45 | 40 | 36 | 34 | 34 | 38 | 46 | 30 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 82 | 77 | 72 | 64 | 59 | 53 | 45 | 60 | 60 | 60 |
| Share Capital | 16 | 16 | 16 | 16 | 15 | 15 | 14 | 14 | 14 | 14 |
| Reserves & Surplus | 66 | 62 | 56 | 48 | 43 | 38 | 38 | 53 | 51 | 48 |
Bal Pharma Income Statement Screener - Profit & Revenue Analysis
Screen Bal Pharma income statement and profit fundamentals.
Analyze BALPHARMA quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Bal Pharma share price evaluation.
| Item | 2026-Mar | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar | 2022-Jun |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 84 | 83 | 67 | 75 | 88 | 97 | 75 | 74 | 74 | 83 | 71 | 93 | 82 | 78 | 70 |
| Expenses | 74 | 74 | 60 | 68 | 78 | 85 | 68 | 66 | 65 | 74 | 64 | 85 | 74 | 71 | 65 |
| EBITDA | 10 | 9 | 7 | 7 | 10 | 12 | 7 | 8 | 8 | 8 | 7 | 8 | 8 | 7 | 5 |
| Operating Profit % | 13.00% | 9.00% | 9.00% | 8.00% | 11.00% | 10.00% | 9.00% | 10.00% | 11.00% | 10.00% | 9.00% | 8.00% | 10.00% | 5.00% | 7.00% |
| Depreciation | 3 | 2 | 3 | 2 | 3 | 2 | 2 | 3 | 3 | 2 | 3 | 2 | 3 | 2 | 2 |
| Interest | 4 | 4 | 4 | 4 | 5 | 4 | 4 | 4 | 5 | 4 | 4 | 4 | 4 | 3 | 2 |
| Profit Before Tax | 3 | 3 | 0 | 1 | 2 | 6 | 1 | 1 | 1 | 2 | 0 | 2 | 1 | 2 | 1 |
| Tax | 0 | -3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 |
| Net Profit | 4 | 5 | 0 | 1 | 2 | 6 | 0 | 1 | 1 | 2 | 0 | 1 | 1 | 2 | 0 |
| EPS | 2.26 | 3.40 | 0.13 | 0.45 | 1.12 | 3.73 | 0.16 | 0.65 | 0.33 | 1.03 | 0.06 | 0.62 | 0.54 | 1.33 | 0.19 |
Bal Pharma Cash Flow Screener - Liquidity Fundamentals
Screen BALPHARMA cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 20 | 23 | -2 | 27 | 22 | 23 | 8 | 1 | 6 | -19 |
| Investing Activities | -15 | -19 | -22 | -10 | -6 | -5 | -8 | -4 | -8 | -14 |
| Financing Activities | -8 | -1 | 24 | -17 | -17 | -20 | 0 | 4 | -6 | 32 |
| Net Cash Flow | -2 | 3 | 0 | 0 | 0 | -2 | 0 | 1 | -8 | -1 |
Bal Pharma Shareholding Pattern Screener
See Bal Pharma shareholding pattern with promoter, FII, and DII holdings.
Check Bal Pharma promoter holding and ownership changes for BALPHARMA on TickJournal.
| Item | 2026-Mar | 2026-Jun | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 50.86% | 50.86% | 50.86% | 50.86% | 50.86% | 50.86% | 51.23% | 51.23% |
| FII Holding | 0.14% | 0.15% | 0.14% | 0.15% | 0.22% | 0.14% | 0.13% | 0.13% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 32.84% | 32.86% | 32.49% | 32.41% | 32.97% | 33.02% | 32.15% | 32.36% |
| Other Holding | 16.16% | 16.13% | 16.51% | 16.58% | 15.94% | 15.99% | 16.49% | 16.28% |
| Shareholder Count | 15,214 | 14,974 | 15,723 | 15,826 | 15,774 | 15,520 | 14,772 | 15,014 |
Bal Pharma Share Dividend Screener - Share Yield Analysis
Check Bal Pharma dividend history with payout and yield data.
View Bal Pharma dividend details including ex-dates and amounts for BALPHARMA stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹1.20 | 1.99% |
| 2024-March | ₹1.20 | 1.43% |
| 2023-March | ₹1.00 | 1.10% |
| 2022-March | ₹1.00 | 1.55% |
| 2021-March | ₹1.00 | 0.93% |
| 2020-March | ₹0.00 | 0.00% |
| 2019-March | ₹1.00 | 3.13% |
| 2018-March | ₹1.00 | 1.43% |
| 2017-March | ₹1.00 | 1.30% |
Bal Pharma Stock Index Membership
See which indices include Bal Pharma stock.
Check BALPHARMA index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Bal Pharma Market Events Screener - Corporate Actions
Get Bal Pharma corporate actions including splits, bonuses, and buybacks.
Check Bal Pharma stock events that may affect BALPHARMA share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-05-27 | 2026-05-27 | Quarterly Result Announcement | NA | 17.37% |
| 2026-02-11 | 2026-02-11 | Quarterly Result Announcement | NA | 7.85% |
| 2025-11-12 | 2025-11-12 | Quarterly Result Announcement | NA | -1.70% |
| 2025-09-25 | 2025-09-25 | Annual General Meeting | NA | -9.36% |
| 2025-09-18 | 2025-09-18 | Dividend | ₹ 1.20 /share | -6.50% |
| 2025-08-11 | 2025-08-11 | Quarterly Result Announcement | NA | -3.59% |
| 2025-05-29 | 2025-05-29 | Quarterly Result Announcement | NA | -6.14% |
| 2025-02-13 | 2025-02-13 | Quarterly Result Announcement | NA | -12.62% |
| 2024-11-14 | 2024-11-14 | Quarterly Result Announcement | NA | -7.93% |
| 2024-09-25 | 2024-09-25 | Annual General Meeting | NA | 14.26% |
| 2024-09-17 | 2024-09-19 | Dividend | ₹ 1.20 /share | 31.47% |
| 2023-12-21 | 2023-12-21 | Extraordinary General Meeting | NA | -10.17% |
| 2023-09-18 | 2023-09-19 | Dividend | ₹ 1.00 /share | 10.53% |
| 2022-09-13 | 2022-09-15 | Dividend | ₹ 1.00 /share | -1.36% |
| 2021-09-16 | 2021-09-18 | Dividend | ₹ 1.00 /share | 6.91% |
Bal Pharma Competitors Screener - Peer Comparison
Screen BALPHARMA competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 469,406 | 40.30 | 61,674 | 12.69% | 11,565 | 62.67 |
| Divis Laboratories | 194,270 | 75.03 | 10,560 | 8.73% | 2,520 | 69.61 |
| Torrent Pharmaceuticals | 190,389 | 75.44 | 13,886 | 20.34% | 2,138 | 53.08 |
| Cipla | 116,459 | 29.67 | 29,045 | 2.24% | 3,870 | 48.42 |
| Zydus Life Science | 115,616 | 22.25 | 27,658 | 17.64% | 5,026 | 59.19 |
| Lupin | 113,325 | 20.85 | 29,039 | 26.75% | 5,356 | 54.70 |
| Mankind Pharma | 105,967 | 53.09 | 14,636 | 14.85% | 1,938 | 50.34 |
| Dr Reddys Laboratories | 102,088 | 24.31 | 35,059 | 3.90% | 4,158 | 31.90 |
| Aurobindo Pharma | 89,736 | 25.44 | 33,385 | 3.21% | 3,376 | 50.49 |
| Laurus Labs | 84,158 | 92.82 | 6,868 | 22.01% | 890 | 59.60 |
Bal Pharma Company Announcements - News Screener
Screen BALPHARMA latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-07-18 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-07-15 | Shareholder Meeting / Postal Ballot-Notice of Postal Ballot | - |
| 2026-06-24 | Appointment of Company Secretary and Compliance Officer | - |
| 2026-06-24 | Closure of Trading Window | - |
| 2026-05-29 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-05-29 | Non Applicability Of Statement Of Deviation & Variation | - |
| 2026-05-27 | Audited Financial Results-Standalone & Consolidated | - |
| 2026-05-27 | Board Meeting Outcome for Outcome Of The Board Meeting | - |
| 2026-05-22 | Announcement under Regulation 30 (LODR)-Meeting Updates | - |
| 2026-05-22 | Compliances-Reg.24(A)-Annual Secretarial Compliance | - |
| 2026-05-18 | Board Meeting Intimation for Intimation Of The Board Meeting | - |
| 2026-05-12 | Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer | - |
| 2026-04-06 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-03-23 | Closure of Trading Window | - |
| 2026-02-16 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-02-11 | Financial Results_31.12.2025 | - |
| 2026-02-11 | Board Meeting Outcome for Outcome Of The Board Meeting_ Standalone And Consolidated Financial Results For The Quarter Ended 31.12.2025. | - |
| 2026-02-09 | Shareholder Meeting / Postal Ballot-Scrutinizer"s Report | - |
| 2026-02-03 | Board Meeting Intimation for Unaudited Financial Results For The Quarter Ended 31.12.2025. | - |
| 2026-01-12 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |